Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Lipid Absorption

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Annals of the rheumatic diseases·2016

Same author

Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study.

Arthritis & rheumatology (Hoboken, N.J.)·2015

Same author

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Lancet (London, England)·2015

Same author

Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.

Annals of the rheumatic diseases·2014

Same author

Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study.

Diabetes research and clinical practice·2013

Same author

Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study.

Annals of the rheumatic diseases·2010

Search research articles

Related Experiment Video

Updated: May 28, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Aggressive lipid-lowering therapy: a clinical imperative

¹Department of Cardiology, Aker Hospital, University of Oslo, Norway.

European Heart Journal

|November 20, 1998

Summary

Lowering low-density lipoprotein cholesterol (LDL-C) significantly reduces coronary heart disease (CHD) risk. Achieving lower LDL-C levels and greater cholesterol reduction provides maximum benefit for patients at risk.

Area of Science:

Cardiology
Preventive Medicine
Pharmacology

Background:

Low-density lipoprotein cholesterol (LDL-C) is a primary factor in atherosclerosis and coronary heart disease (CHD) development.
Effective LDL-C reduction is crucial for managing CHD risk, yet many patients do not meet treatment targets.

Purpose of the Study:

To review the evidence on LDL-C reduction and its impact on CHD risk.
To emphasize the importance of aggressive lipid-lowering therapy and the degree of cholesterol reduction achieved.

Main Methods:

Analysis of epidemiological and clinical studies.
Review of data from trials using various lipid-lowering agents, including fibrates, bile acid sequestrants, and HMG-CoA reductase inhibitors.

Main Results:

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Related Experiment Videos

Last Updated: May 28, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

HMG-CoA reductase inhibitors offer substantial LDL-C reduction and significant decreases in coronary and all-cause mortality.
Greater LDL-C reduction correlates with a more pronounced decrease in major coronary events.
The extent of cholesterol lowering, not just the final LDL-C level, is critical for CHD risk reduction.

Conclusions:

Aggressive lipid-lowering therapy, particularly with HMG-CoA reductase inhibitors, is effective in reducing CHD risk.
Maximizing the degree of LDL-C reduction offers the greatest clinical benefit for patients.
Patients achieving the most significant changes in LDL-C levels experience the most substantial benefits from treatment.